<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cardiff Oncology Inc — News on 6ix</title>
<link>https://6ix.com/company/cardiff-oncology-inc</link>
<description>Latest news and press releases for Cardiff Oncology Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cardiff-oncology-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835592878dffbe2df0eaea7.webp</url>
<title>Cardiff Oncology Inc</title>
<link>https://6ix.com/company/cardiff-oncology-inc</link>
</image>
<item>
<title>Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-host-key-opinion-leader-discussion-on-onvansertibs-promising-single-agent-activity</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-host-key-opinion-leader-discussion-on-onvansertibs-promising-single-agent-activity</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss data from an investigator-initiated trial on onvansertib's single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The webinar will take place on Thursday, April 30th, 2026, at 11:00 a.m.</description>
</item>
<item>
<title>Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-presents-preclinical-data-on-its-plk1-inhibitor-onvansertib-in-combination-with-a-her2-targeted-adc-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-presents-preclinical-data-on-its-plk1-inhibitor-onvansertib-in-combination-with-a-her2-targeted-adc-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Fri, 17 Apr 2026 20:01:00 GMT</pubDate>
<description>Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment optionsSAN DIEGO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will present new preclinical data in a poster a</description>
</item>
<item>
<title>Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-key-leadership-appointments-to-strengthen-executive-team-for-next-phase-of-growth</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-key-leadership-appointments-to-strengthen-executive-team-for-next-phase-of-growth</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer</description>
</item>
<item>
<title>Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-host-key-opinion-leader-discussion-focusing-on-first-line-ras-mutated-metastatic-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-host-key-opinion-leader-discussion-focusing-on-first-line-ras-mutated-metastatic-colorectal-cancer</guid>
<pubDate>Fri, 20 Mar 2026 11:00:00 GMT</pubDate>
<description>SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss the emergent treatment landscape in first-line RAS-mutated metastatic colorectal cancer (mCRC). The webinar will take place on Wednesday, March 25th, 2026, at 4:30 p.m. ET. The webinar will feature KOLs Sco</description>
</item>
<item>
<title>Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-present-preclinical-data-with-highly-specific-plk1-inhibitor-onvansertib-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-present-preclinical-data-with-highly-specific-plk1-inhibitor-onvansertib-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumor activity and reversal of resistance with PLK1 inhibition</description>
</item>
<item>
<title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-participate-in-three-upcoming-investor-conferences-1</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-participate-in-three-upcoming-investor-conferences-1</guid>
<pubDate>Thu, 26 Feb 2026 21:01:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/2</description>
</item>
<item>
<title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences </title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-participate-in-three-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-participate-in-three-upcoming-investor-conferences</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to</description>
</item>
<item>
<title>Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-reports-full-year-2025-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-reports-full-year-2025-results-and-provides-business-update</guid>
<pubDate>Tue, 24 Feb 2026 21:30:00 GMT</pubDate>
<description>Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb.</description>
</item>
<item>
<title>Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to</description>
</item>
<item>
<title>Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-positive-randomized-120500975</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-positive-randomized-120500975</guid>
<pubDate>Tue, 27 Jan 2026 12:05:00 GMT</pubDate>
<description>- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in</description>
</item>
<item>
<title>Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-executive-leadership-120000503</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-executive-leadership-120000503</guid>
<pubDate>Tue, 27 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company’s next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a seasoned biotech executiv</description>
</item>
<item>
<title>Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-clinical-data-210500512</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-clinical-data-210500512</guid>
<pubDate>Mon, 08 Dec 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting. In this Phase 1 dose escalation trial (N=9), onvansertib</description>
</item>
<item>
<title>Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-present-sidoti-end-120000335</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-present-sidoti-end-120000335</guid>
<pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM E</description>
</item>
<item>
<title>Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-present-piper-sandler-120000394</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-present-piper-sandler-120000394</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference, which is taking place from December 2-4, 2025. Details of the presentation can be found below. Presenters: Mark Erlander, PhD (CEO) Date:</description>
</item>
<item>
<title>Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-reports-third-quarter-210500009</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-reports-third-quarter-210500009</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhib</description>
</item>
<item>
<title>Cardiff Oncology to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-participate-two-upcoming-210100236</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-participate-two-upcoming-210100236</guid>
<pubDate>Tue, 04 Nov 2025 21:01:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025. Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1 MeetingsPresenters: Mark Erlander, PhD (CEO) Date: 11/11/2025Time: 9:30 AM ET Stifel 2025</description>
</item>
<item>
<title>Cardiff Oncology to Participate in Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-participate-three-upcoming-200500133</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-participate-three-upcoming-200500133</guid>
<pubDate>Thu, 28 Aug 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025. Details of the events can be found below. Wells Fargo 20th Annual Healthcare Conference Format: 1x1 Meetings Date: 09/05/2025Location: Encore Boston Harbor, Everett, MA Morgan S</description>
</item>
<item>
<title>Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-positive-data-200700094</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-announces-positive-data-200700094</guid>
<pubDate>Tue, 29 Jul 2025 20:07:00 GMT</pubDate>
<description>– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib continues to be well-tolerated and demonstrates a dose dependent response for all endpoints including ORR, early tumor shrinkage and depth of response – – Company will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, July 2</description>
</item>
<item>
<title>Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-reports-second-quarter-200500960</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-reports-second-quarter-200500960</guid>
<pubDate>Tue, 29 Jul 2025 20:05:00 GMT</pubDate>
<description>- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced positive data from investigator-initiated trial of onvansertib in combination with paclitaxel in mTNBC at ASCO 2025 - - Cash and investments of $71.0 million as of June 30, 2025, projected runway into Q1 2027 - - Company to hold a conference call</description>
</item>
<item>
<title>Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC</title>
<link>https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-appoints-dr-roger-200500215</link>
<guid isPermaLink="true">https://6ix.com/company/cardiff-oncology-inc/news/cardiff-oncology-appoints-dr-roger-200500215</guid>
<pubDate>Tue, 17 Jun 2025 20:05:00 GMT</pubDate>
<description>– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) – SAN DIEGO, June 17,</description>
</item>
</channel>
</rss>